Clear cell renal cell carcinoma

9 trials 3 recruiting MedDRA PT
9 Registered trials
3 Recruiting
9 Unique sponsors
7 Unique IMPs
6 Commercial trials
Drug classes (ATC)
— ATC code not specified 6
S Ophthalmology/ENT (ATC S) 1
L Oncology (ATC L) 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 4 substances
Checkpoint inhibitor (CTLA-4) 1 substance
Checkpoint inhibitor (PD-1) 1 substance
Kinase inhibitor 1 substance
Phase II: 3 Phase IV: 1 Phase I: 4 Phase I (First in Human): 1

Filter these 9 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 9 trials

Phase II

3 trials
  • Daiichi Sankyo Inc. Commercial
    RALUDOTATUG DERUXTECAN
    2024-513307-13-00 5 countries 2025 n=73
    Ended
  • Fondazione IRCCS Istituto Nazionale Dei Tumori Academic
    IMP not specified
    2024-514058-59-00 1 country 2018 n=49
    Ended
  • Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting Academic
    IPILIMUMAB; NIVOLUMAB
    2024-515514-40-00 1 country 2022 n=69
    Ended

Phase IV

1 trial
  • Institut Gustave Roussy Academic
    CABOZANTINIB; NIVOLUMAB
    2024-516650-22-00 1 country 2025 n=50
    Recruiting

Phase I

4 trials
  • Exelixis Inc. Commercial
    IMP not specified
    2024-515617-18-00 5 countries 2022 n=140
    Ended
  • Genentech Inc. Commercial
    IMP not specified
    2023-509266-38-00 2 countries n=23
    Pending
  • Novartis Pharma AG Commercial
    IMP not specified
    2022-502381-25-01 4 countries 2024 n=97
    Ended
  • Xencor Inc. Commercial
    IMP not specified
    2024-513619-28-00 3 countries 2025 n=48
    Recruiting

Phase I (First in Human)

1 trial
  • ITM Oncologics GmbH Commercial
    177LU-DPI-4452; 68GA-DPI-4452; ACETAZOLAMIDE
    2023-504254-35-00 2 countries 2023 n=97
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Exelixis Inc. Commercial 1 Phase I 0
Genentech Inc. Commercial 1 Phase I 0
Novartis Pharma AG Commercial 1 Phase I 0
Xencor Inc. Commercial 1 Phase I 1
Daiichi Sankyo Inc. Commercial 1 Phase II 0
ITM Oncologics GmbH Commercial 1 Phase I (First in Human) 1
Fondazione IRCCS Istituto Nazionale Dei Tumori Academic 1 Phase II 0
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting Academic 1 Phase II 0
Institut Gustave Roussy Academic 1 Phase IV 1
New trials by year
2022
2
2023
1
2024
1
2025
3
← All indication landscapes